Latest News

With its stock down 15% over the past three months, it is easy to disregard CTS Eventim KGaA (ETR:EVD). But if you pay...

Shareholders might have noticed that LVMH Moët Hennessy - Louis Vuitton, Société Européenne ( EPA:MC ) filed its annual...

Devyser Diagnostics AB (publ) ( STO:DVYSR ) shareholders are probably feeling a little disappointed, since its shares...

Naspers (JSE:NPN) has had a rough three months with its share price down 27%. But if you pay close attention, you might...

The Gapwaves AB (publ) ( STO:GAPW B ) share price has fared very poorly over the last month, falling by a substantial...

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...

Odfjell SE ( OB:ODF ) shareholders are probably feeling a little disappointed, since its shares fell 7.6% to kr122 in...

OrganoClick AB (publ) ( STO:ORGC ) missed earnings with its latest yearly results, disappointing overly-optimistic...

With a price-to-earnings (or "P/E") ratio of 37.3x Carasso Real Estate Ltd ( TLV:CRSR ) may be sending very bearish...

A lackluster earnings announcement from Eik fasteignafélag hf. ( ICE:EIK ) last week didn't sink the stock price. We...

When close to half the companies in Israel have price-to-earnings ratios (or "P/E's") below 16x, you may consider...

It's shaping up to be a tough period for United Bankers Oyj ( HEL:UNITED ), which a week ago released some...

Shareholders might have noticed that Olvi Oyj ( HEL:OLVAS ) filed its full-year result this time last week. The early...

Why Tempus AI’s new lung cancer screening partnership matters Tempus AI (TEM) just announced a collaboration with Median Technologies to bring FDA cleared eyonis LCS lung cancer screening software into the Tempus Pixel platform, putting more focus on early detection and clinical workflows. See our latest analysis for Tempus AI. The Median partnership arrives after a choppy stretch for Tempus AI, with a 1 day share price return of 2.30% to US$51.95, following a 30 day share price return...

Crane NXT recently reported past quarterly results showing around 20% year-on-year sales growth in Q4 2025 and 11% for 2025 overall, driven by strong demand in its currency and authentication technology businesses, new wins across 20 currency denominations, and renewed multiyear contracts with major sports leagues. The company is also expanding capacity in its international currency operations and moving to acquire Antares Vision by mid-2026, highlighting how its micro-optics and...

Earnings and new subsidiaries set the tone for CapitaLand Investment (SGX:9CI) CapitaLand Investment (SGX:9CI) has been in focus after its full year 2025 earnings showed sales of S$2,133 million and net income of S$145 million, along with wide ranging subsidiary incorporations across Asia. See our latest analysis for CapitaLand Investment. The earnings release and new subsidiaries land against a backdrop of a 16.9% 90 day share price return and a 33.4% 1 year total shareholder return. By...

Recent performance snapshot for ServisFirst Bancshares ServisFirst Bancshares (SFBS) has drawn investor attention after a recent share price move, with the stock around $86.14 and showing mixed return patterns across the past year and multi year periods. See our latest analysis for ServisFirst Bancshares. Recent trading has been relatively steady, with a 30 day share price return of 10.07% and a 90 day share price return of 26.27%, while the 1 year total shareholder return of 0.93% decline...

On 12 February 2026, BioLife Solutions, Inc. announced a multi-year agreement to distribute Qkine Limited’s cytokine and growth factor products globally for cell and gene therapy manufacturing, with plans to integrate select products into BioLife’s CellSeal® Connect vial system. This deal broadens BioLife’s reach into the US$500 million cytokines market, which third-party research suggests could reach about US$1.00 billion by 2030, directly linking its biopreservation tools with critical CGT...

If you are wondering whether Flex stock still offers value after a strong run, this article will help you unpack what the current price might be implying about the business. The shares recently closed at US$64.24, with returns of 0.4% over 7 days, a 0.9% decline over 30 days, 0.9% year to date and 51.1% over 1 year. This naturally raises questions about how much of the story is already in the price. Recent news coverage around Flex has focused on its role as a large electronics manufacturing...

What H&R Real Estate Investment Trust’s Recent Returns Tell You H&R Real Estate Investment Trust (TSX:HR.UN) has quietly posted a 10.5% total return over the past year and a 36.4% total return over five years, even as recent month performance has been softer. See our latest analysis for H&R Real Estate Investment Trust. The recent 7 day share price return of 3.6% decline and 30 day share price return of 4.4% decline contrast with a 90 day share price return of 5.7% and a 1 year total...

Upstart Holdings, Inc. reported fourth‑quarter 2025 revenue of US$296.09 million and net income of US$18.64 million, marking a return to profitability for both the quarter and full year compared with losses in 2024. Alongside these results, Upstart unveiled an extensive leadership reshuffle and issued multi‑year revenue guidance through 2028, signaling a shift in how it balances growth ambitions with execution and governance. We’ll now examine how Upstart’s return to profitability and...

Conference spotlight and access program put Syndax Pharmaceuticals (SNDX) in focus Syndax Pharmaceuticals (SNDX) is back on investors radar after positive Revuforj trial data, a new Managed Access Program with the World Orphan Drug Alliance, and a high profile slot at Guggenheim Securities Emerging Outlook Biotech Summit 2026. See our latest analysis for Syndax Pharmaceuticals. Despite a softer patch recently, with a 1 day share price return of a 3.12% decline and a 7 day share price return...

NeoVolta (NEOV) has just posted its Q2 2026 numbers, with Q1 2026 revenue at US$6.7 million and a net loss of US$1.2 million, translating into basic EPS of a US$0.04 loss. The company has seen quarterly revenue move from US$0.6 million in Q1 2025 through US$1.1 million in Q2 2025, US$2.0 million in Q3 2025 and US$4.8 million in Q4 2025 to US$6.7 million in Q1 2026, while EPS over the same stretch ranged from a loss of US$0.03 to a loss of US$0.05 per share. For investors, the latest set of...

Why EPAM Systems (EPAM) Is Back on Investors’ Radar Fresh attention on EPAM Systems (EPAM) follows research highlighting its stronger earnings outlook and value metrics versus Infosys, positioning the US software services group as a comparatively attractive IT services option. See our latest analysis for EPAM Systems. At a share price of US$166.37, EPAM has seen a sharp 21.75% 1 month share price decline and a 37.48% 1 year total shareholder return decline. This suggests recent earnings and...